Stock INIT INITIATOR PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up

All News Initiator Pharma A/S

Equities

INIT

DK0060775872

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-16 pm EDT 		5-day change 1st Jan Change
9.05 SEK +1.12% Intraday chart for Initiator Pharma A/S -1.63% -2.06%
May. 10 Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Feb. 23 Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Initiator Pharma A/S - Resolutions of the annual general meeting 2024
AQ
Initiator Pharma Q1 2024 - Focus on sealing a deal
AQ
INITIATOR PHARMA: Q1 2024 REPORT
PU
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Notice to AGM in Initiator Pharma
AQ
Annual report and Remuneration report 2023 for Initiator Pharma A/S
AQ
Initiator Pharma's pudafensine preclinical pharmacology results published in the British Journal of Pharmacology
AQ
Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology
AQ
Initiator Pharma - Q4 2023 – Breathing optimism
AQ
INITIATOR PHARMA: YEAR END REPORT 2023
AQ
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Initiator Pharma Issues New Shares for Debt Conversion
MT
MAC Clinical Research converts its receivable into shares in Initiator Pharma
AQ
Initiator Pharma A/S - Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021
AQ
Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021
AQ
Initiator Pharma expands its position to a broader Sexual Health Franchise and intensifies its business development efforts
AQ
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts
CI
Initiator Pharma Q3 - A historical quarter
AQ
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INIT Stock
  4. News Initiator Pharma A/S